Monitor for any shareholder dissent on executive compensation, though this routine filing suggests business as usual.
XENE drugs
XENE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 23 $55.41entry
- T+1 · 7mo ago −0.31%α −1.09% · $55.24
- T+5 · 7mo ago +0.61%α −0.86% · $55.75
- T+20 · 6mo ago −1.32%α −5.95% · $54.68
- T+60 · 4mo ago +19.18%α +14.17% · $66.04
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Xenon Pharmaceuticals filed a definitive proxy statement for its 2025 annual meeting, proposing the re-election of eight directors, approval of executive compensation, and reappointment of its auditor. This routine filing follows a recent amendment to its equity incentive plan, indicating ongoing governance activities.
Key Financial Metrics
Key Facts
- Filing is a definitive proxy statement (DEFA14A) for the 2025 annual meeting
- Proposes re-election of eight directors including Dawn Svoronos, Gillian Cannon, and Justin Gover
- Seeks approval of executive compensation and reappointment of PwC as auditor
- Follows recent 8-K filing amending the equity incentive plan
Financial Impact
Routine governance filing with no immediate financial impact
Risk Factors
- Potential shareholder dissent on executive compensation
- Board continuity risk if any directors are not re-elected
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-170335 |
| Document: 0001193125-26-170335-index-headers.html | 0001193125-26-170335 |
| Document: 0001193125-26-170335-index.html | 0001193125-26-170335 |
| Document: 0001193125-26-170335.txt | 0001193125-26-170335 |
Track record
19 reports on XENE
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
- Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
- Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers